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Edited by Robert BaroukiAbstract Tumor growth of colorectal cancers accompanies
upregulation of cyclooxygenase-2, which catalyzes a conversion
step from arachidonic acid to prostaglandin H2 (PGH2). Here,
we compared the expression levels of thromboxane synthase
(TXS), which catalyzes the conversion of PGH2 to thromboxane
A2 (TXA2), between human colorectal cancer tissue and its
accompanying normal mucosa. It was found that TXS protein
was consistently upregulated in the cancer tissues from diﬀerent
patients. TXS was also highly expressed in human colonic cancer
cell lines. Depletion of TXS protein by the antisense oligonucleo-
tide inhibited proliferation of the cancer cells. This inhibition was
rescued by the direct addition of a stable analogue of TXA2. The
present results suggest that overexpression of TXS and subse-
quent excess production of TXA2 in the cancer cells may be in-
volved in the tumor growth of human colorectum.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Colorectal cancer is one of the major causes of cancer deaths
in the Western world [1,2]. A large number of human colorec-
tal cancers show overexpression of cyclooxygenase-2 (COX-2),
which catalyzes a key conversion step from arachidonic acid to
PGH2 [3–8]. Long-term use of the non-steroidal anti-inﬂam-
matory drugs, which inhibit COX-2, has been suggested to
be associated with a low risk of colorectal cancer although
its molecular mechanism of action is at the stage of elucidation
[9,10]. COX-2 is proposed as a potential target for cancer pre-
vention [10,11]. However, clinical trial of COX-2 inhibitorsAbbreviations: TXA2, thromboxane A2; TXB2, thromboxane B2; TXS,
thromboxane synthase; TP, thromboxane A2 receptor; STA2,
9,11-epithio-11,12-methano-thromboxane A2; COX, cyclooxygenase;
PECAM-1, platelet-endothelial cell adhesion molecule-1; GAPDH,
glyceraldehyde 3-phosphate dehydrogenase; PG, prostaglandin
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doi:10.1016/j.febslet.2006.05.007was found to be associated with an elevated risk of cardiovas-
cular events [12–14].
The COX-2 inhibitors block the production of a number of
biologically active prostanoids such as PGE2, PGD2, PGF2a,
PGI2 and thromboxane A2 (TXA2). In a downstream of the
COX pathway, thromboxane synthase (TXS) catalyzes the
conversion of PGH2 to TXA2, which is known as a potent in-
ducer of platelet aggregation and vasoconstriction [15]. In the
human colon, the production of TXA2 is greatly increased in
inﬂammatory bowel diseases [16]. In isolated rat and human
distal colon, we found that TXA2 is a novel secretagogue for
Cl secretion [17,18]. For example, an anti-tumor drug irino-
tecan stimulates the release of the TXA2 from the subepithelial
layer of rat colonic mucosa, resulting in the enhanced Cl
secretion [17,19]. This TXA2-elicited pathway may explain
the side eﬀect of irinotecan-induced diarrhea.
So far, the expression level of TXS and function of TXA2 in
human colorectal cancer have not been reported. In the present
study, we have found that TXS is upregulated in the tissue of
human colorectal carcinoma, and that TXA2 stimulates the
cancer cell proliferation.2. Materials and methods
2.1. Chemicals
9,11-Epithio-11,12-methano-thromboxane A2 (STA2; ONO Pharma-
ceutical Co., Osaka, Japan), sodium 4-[a-hydroxy-5-(1-imidazolyl)-2-
methylbenzyl]-3,5-dimethylbenzoate dihydrate (Y-20811; Yoshitomi
Pharmaceutical Industries, Fukuoka, Japan), sodium (E)-3-[4-(3-pyr-
idylmethyl)phenyl]-2-methylacrylate (OKY-1581; Eisai Co., Tsukuba,
Japan), sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl)-ethylidene]-
6,11-dihydrobenz[b,e] oxepine-2-carboxylate monohydrate (KW-3635;
Kyowa Hakko Kogyo Co., Shizuoka, Japan) were the generous gifts
of their respective manufacturers. Thromboxane B2 (TXB2) was
obtained from Wako Pure Chemical Industries (Osaka, Japan).
2.2. Human colonic cancer cell lines
HT-29 and T-84 cells were obtained from Dainippon Pharmaceuti-
cal Co. (Osaka, Japan) and were maintained in McCoy’s 5A medium
supplemented with 10% fetal bovine serum (FBS) and Dulbecco’s
modiﬁed Eagle medium/nutrient mixture F-12 (1:1 mixture) supple-
mented with the 10% FBS, respectively. WiDr cells were obtained from
Japanese Cancer Research Resources Bank (Tokyo, Japan) and were
maintained in the minimum essential medium (Earle’s) supplemented
with non-essential amino acids and 10% FBS. KM12-L4 cells [20] wereblished by Elsevier B.V. All rights reserved.
Fig. 1. Upregulation of TXS protein in human colorectal carcinomas. (A) Western blotting for detecting proteins of TXS (60 kDa) and COX-2
(72 kDa) in paired normal mucosa (N) and adenocarcinoma (C). Location of each carcinoma (C, cecum; A, ascending colon; T, transverse colon;
S, sigmoid colon; R, rectum) and stage of the carcinoma according to the TNM clinical classiﬁcation by International Union Against Cancer (0, I,
II, III or IV) are indicated in the upper parenthesis. Age and sex (M, male; F, female) of patients are indicated in the lower parenthesis. (B)
Speciﬁcity of the antibodies for the bands of 60 kDa (TXS) and 72 kDa (COX-2) was conﬁrmed by using the corresponding blocking peptide
(BP). (C) Immunostaining for TXS in tissues of the carcinoma and accompanying normal mucosa. Representative pictures of carcinoma (left lane)
and normal mucosa (right lane) are shown. HE, histology of the tissue was checked by hematoxylin–eosin staining. Scale bars, 200 lm (left) and
100 lm (right). TXS, tissue sections were immunostained with the anti-TXS monoclonal antibody. Scale bars, 200 lm (upper left), 100 lm (upper
right and lower left) and 50 lm (lower right). Control, control staining in the absence of the primary antibody. Scale bars, 200 lm (left) and
100 lm (right).
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and maintained in minimum essential medium (Earle’s) supplemented
with 10% FBS.
2.3. Tissue procurement
Human colorectal carcinoma specimens were obtained from surgical
resection of Japanese patients at University of Toyama Hospital in
accordance with the recommendations of the Declaration of Helsinki
and with the ethics committee approval. Informed consent was ob-
tained from all the patients. In all cases, the control specimens were
collected from accompanying normal mucosa, which were 5–10 cm
apart from the carcinoma. The cancer tissue and the normal epithelial
layer were carefully isolated from the resected colon with scissors and
forceps. These samples were free from the serosa and muscularis pro-
pria. The blood vessels around the tissues were carefully removed. The
clinical and histological classiﬁcations were carried out by expert
pathologists according to the general rules edited by Japanese Re-
search Society for Cancer of the Colon and Rectum and the TNM clin-
ical classiﬁcation by International Union Against Cancer.
2.4. RNA isolation, Northern blotting and TaqMan assay
Total RNAs from the human tissues and poly A+ RNAs from hu-
man cancer cell lines were prepared as described elsewhere [21], and
10 lg of total RNA or 2.5 lg of poly A+ RNA was separated on 1%
agarose/formamide gel and transferred onto a nylon membrane
(Zeta-probe GT, Bio-Rad). PCR products of TXS (474 bp; nucleotide
positions 333–806), COX-2 (605 bp; nucleotide positions 527–1131),
thromboxane A2 receptor (TP) (618 bp; nucleotide positions 322–
939) and glyceraldehyde 3-phosphate dehydrogenase (GAPDH)(493 bp; nucleotide positions 449–941) were used for Northern blotting
[21]. Amounts of TXS, COX-2, platelet-endothelial cell adhesion mol-
ecule-1 (PECAM-1) and NF-E2 were quantiﬁed by real-time PCR
(TaqMan assay) using ABI PRISM 7700 sequence detector. In the
assay, amount of GAPDH was measured as control.
2.5. Western blotting
Membrane fractions of the human colorectal tissues and human co-
lonic cancer cell lines were prepared, and Western blotting was per-
formed [21,22]. The blotting was performed with 80 lg of membrane
protein. The intensity of the speciﬁc band was quantiﬁed by using
ATTO densitograph 4.0 software. Anti-human TXS polyclonal anti-
body raised against a peptide corresponding to amino acids 359–377
of the TXS and anti-human COX-2 polyclonal antibody raised against
a peptide corresponding to amino acids 567–599 of the COX-2 (Cay-
man Chemical, Ann Arbor, MI, USA) were used at 1:500 dilution.
For negative control, the antibody was pre-incubated with the corre-
sponding blocking peptide (1:1). Anti-ovine COX-1 monoclonal anti-
body (Cayman Chemical) was used at 1:200 dilution. Horse-radish
peroxidase-conjugated anti-rabbit or anti-goat IgG was used as a sec-
ondary antibody (1:1000–1:2000 dilution).
2.6. Immunohistochemistry
Fresh-frozen tissues embedded in the Tissue-Tek O.C.T. compound
(Sakura Finetechnical Co., Tokyo, Japan) were cut into 6 lm thick sec-
tions. The sections ﬁxed in acetone for 5 min were stained by indirect
immunoperoxidase technique as previously described [23]. Anti-human
TXSmonoclonal antibody (Tu¨-300; Biogenesis, Poole, UK) was used at
1:200 dilution. The sections were counterstained with 5% methyl green.
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Cell proliferation was assessed by counting the number of cells in a
12-well culture plate. In each well, 1 · 105 cells were seeded and cul-
tured for 2 days in the minimum essential medium (Earle’s) supple-
mented with 0.3% FBS. The mean cell number from 3 to 4
independent wells treated with the same drug was obtained in one
experiment, and the mean values from 4 to 6 experiments on diﬀerent
days were averaged.
2.8. Antisense strategy
The ﬂuorescein isothiocyanate (FITC)-labeled Morpholino anti-
sense oligonucleotide for TXS was purchased from Gene Tools (Cor-
vallis, OR, USA), which matches the nucleotide 1–25 of TXS. As a
negative control, the 4-mismatch oligonucleotide (positions of mis-
match; 3, 7, 18 and 22) was used. The oligonucleotide (1.4 lM) was
introduced into the KM12-L4 cells in the presence of ethoxylated poly-
ethylenimine (0.6 lM), a weakly basic delivery reagent (Gene Tools).
The cells were treated with the oligonucleotide for 4 h. After the treat-
ment, the cells were cultured for 2 days in the presence and absence of
STA2 or/and KW-3635.
2.9. DNA fragmentation assay
The KM12-L4 cells were treated with 20 lM of KW-3635 for 2 days.
Then, DNA was extracted from the cells by using the SepaGene kit
(Sanko Jyunyaku Co., Tokyo, Japan), and 1.5 lg of DNA was sepa-
rated on 2% agarose gel. The gel was stained with ethidium bromide
(0.5 lg/ml). For positive control, the cells were treated with 10 lM
of anisomycin for 12 h.
2.10. Statistics
Results are shown as means ± S.E.M. Diﬀerences between groups
were analyzed by one-way ANOVA, and correction for multiple com-
parisons was made by using Dunnett’s multiple comparison test or
Tukey’s multiple comparison test. Statistically signiﬁcant diﬀerences
were assumed at P < 0.05.Fig. 2. Expression of TXS in human colonic cancer cell lines. (A)
Northern blotting for detecting TXS and COX-2 mRNAs in human
cancer cell lines. KM12-L4, T-84, HT-29 and WiDr are colonic cancer
cell lines. HL-60, a promyelocytic leukemia cell line; HeLa, a cervical
cancer cell line; A549, a lung carcinoma cell line. The membrane was
probed with TXS (2.2 kb; upper lane), then with COX-2 (4.6 kb;
middle lane), and ﬁnally with GAPDH (1.4 kb; lower lane). (B)
Western blotting for detecting TXS and COX-2 proteins in human
colonic cancer cell lines. Speciﬁcity of the antibodies for the bands of
60 kDa (TXS) and 72 kDa (COX-2) was conﬁrmed by using the
corresponding blocking peptide (BP).3. Results
3.1. Upregulation of TXS in the tissue of human colorectal
cancer
In the present study, human colorectal tissues of well or
moderately diﬀerentiated adenocarcinomas and accompanying
normal mucosa from the patients and membrane fractions
from each tissue were used. Fig. 1A shows Western blots for
detecting TXS (60 kDa) and COX-2 (72 kDa) proteins and
Fig. 1B shows the speciﬁcity of the antibodies for these bands.
Interestingly, an increase in the expression level of TXS protein
was observed in 10 out of 10 carcinomas in comparison with
that of the accompanying normal tissue (Fig. 1A). Upregula-
tion of COX-2 protein was found as previously reported [4].
In the fresh-frozen tissue sections, the cells in cancer tissues
showed clear immunoreactivity for TXS (Fig. 1C, left). Such
immunoreactivity was weak in normal epithelial cells in the
accompanying colonic mucosa (Fig. 1C, right).
Corresponding to the present ﬁnding of TXS protein overex-
pression, TXS mRNA was also overexpressed in 10 out of 10
carcinomas compared with the level in the normal mucosa
(Supplementary material, Fig. S1A). In contrast, no upregula-
tion of TP mRNA was observed in the carcinoma (Fig. S1A).
COX-2 mRNA was overexpressed in the carcinoma (Fig. S1A)
as previously reported [3]. The overexpression of TXS and
COX-2 mRNAs in the present carcinoma samples was not sig-
niﬁcantly correlated with that of PECAM-1 [24], an endothe-
lial marker, suggesting that the overexpression was not due
to angiogenesis-derived increase of blood cells (Supplementary
material, Fig. S1B and C).3.2. Expression of TXS in human colonic cancer cell lines
In human colonic cancer cell lines such as KM12-L4, T-84,
HT-29 and WiDr, signiﬁcant expression levels of TXS mRNA
(Fig. 2A) and TXS protein (Fig. 2B) were observed. In non-co-
lonic cancer cell lines such as HL-60 and HeLa cells, no obvi-
ous expression of TXS mRNA was observed (Fig. 2A).
Signiﬁcant expression levels of COX-2 mRNA (Fig. 2A) and
COX-2 protein (Fig. 2B) were observed in KM12-L4, HT-29
and WiDr cells.
3.3. Inhibition of the cancer cell proliferation by TXS inhibitors
and stimulation of the proliferation by a stable analogue of
TXA2
TXS inhibitors such as OKY-1581 [25] and Y-20811 [26] sig-
niﬁcantly inhibited the proliferation of KM12-L4 colonic can-
cer cells (Fig. 3A–C), suggesting that the product of TXS has a
proliferative eﬀect. Thus, eﬀect of STA2, a stable analogue of
TXA2, on the cell proliferation was tested. STA2 was previously
conﬁrmed to mimic the eﬀect of endogenous TXA2 in rat and
human colonic mucosa [18,19]. STA2 signiﬁcantly accelerated
the proliferation of KM12-L4 cells, whereas TXB2 was ineﬀec-
tive (Fig. 3D–E). On the other hand, neither STA2 nor TXB2
stimulated the migration of the cells (data not shown).
Fig. 3. Eﬀects of OKY-1581, Y-20811, STA2 and TXB2 on the cell proliferation of a human colonic cancer cell line. (A) Eﬀects of TXS inhibitors on
the cell proliferation. OKY-1581 (1 lM) or Y-20811 (5 lM) was added just after seeding of the KM12-L4 cells. n = 5–6; **P < 0.01; NS, not
signiﬁcant (P > 0.05). (B) The concentration-dependent eﬀects of OKY-1581. n = 5; *P < 0.05; **P < 0.01. (C) The concentration-dependent eﬀects of
Y-20811. n = 5; *P < 0.05; **P < 0.01. (D) Eﬀects of STA2 and TXB2 on the cell proliferation. STA2 (0.1 lM) or TXB2 (0.1 lM) was added just after
seeding of the KM12-L4 cells. n = 6; **P < 0.01; NS, not signiﬁcant (P > 0.05). (E) The concentration-dependent eﬀects of STA2. n = 5; *P < 0.05;
**P < 0.01. (F) Concentration-dependent eﬀects of TXB2. n = 5.
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oligonucleotide for TXS
An antisense strategy was employed to deplete endogenous
TXS protein in the KM12-L4 colonic cancer cells (Fig. 4A).
This strategy decreased TXS protein, while it had no eﬀect
on the expression levels of COX-1 and COX-2 (Fig. 4A).
Depletion of TXS by the antisense oligonucleotide signiﬁcantly
inhibited the cell proliferation (Fig. 4B), while it had no signif-
icant eﬀect on the cell migration (not shown). In the negative
control experiments using the 4-mismatch oligonucleotide,
both the cell proliferation (Fig. 4B) and the cell migration
(not shown) were normal.
Inhibition of the cell proliferation by the antisense oligonu-
cleotide for TXS was rescued by the direct application of STA2
(Fig. 4C). Furthermore, STA2 was eﬀective in the cells treated
with the 4-mismatch oligonucleotide (Fig. 4D).
3.5. Inhibition of the cancer cell proliferation by a TP antagonist
The STA2-induced cell proliferation was inhibited by KW-
3635 [27], a speciﬁc TP antagonist (Fig. 5A). In the absenceof STA2, the basal cell proliferation was also inhibited by
KW-3635 (Fig. 5B), suggesting that endogenously released
TXA2 acts on the receptor in the cancer cells and stimulates
the cell proliferation. Similar eﬀects of KW-3635 and STA2
plus KW-3635 were observed in the cells treated with the anti-
sense oligonucleotide for TXS (Fig. 5C) or the 4-mismatch
oligonucleotide (Fig. 5D). KW-3635 caused no apoptosis on
the cells (Supplementary material, Fig. S2A). No change of
the viability was observed in the cells treated with KW-3635
(Supplementary material, Fig. S2B).4. Discussion
In the present study, we have found that TXS is overexpres-
sed in human colorectal cancer tissues (Figs. 1 and S1A), and
that TXS is signiﬁcantly expressed in the colonic cancer cell
lines (Fig. 2). The expression level of TP in the cancer tissues
was similar to that in the normal mucosa (Fig. S1A). The cancer
cell proliferation was inhibited by TXS inhibitors (Fig. 3A–C),
Fig. 4. Eﬀects of antisense oligonucleotide for TXS on the proliferation of human colonic cancer cell line. (A) Western blotting showing that the
speciﬁc antisense oligonucleotide for TXS (TXS-AS) greatly reduced the expression of TXS protein (60 kDa) in KM12-L4 cells, while the 4-mismatch
oligonucleotide (4-mis) was ineﬀective. Expression levels of COX-1 (70 kDa) and COX-2 (72 kDa) in these cells are also shown. (B) Eﬀects of TXS-
AS and 4-mis on the cell proliferation. n = 4; **P < 0.01; NS, not signiﬁcant (P > 0.05). (C) Eﬀect of STA2 on the TXS-depleted KM12-L4 cells. STA2
(0.1 lM) was added just after treating the cells with TXS-AS or vehicle. n = 6; *P < 0.05; **P < 0.01; NS, not signiﬁcant (P > 0.05). (D) Eﬀect of STA2
on the 4-mis-treated KM12-L4 cells. STA2 (0.1 lM) was added just after treating the cells with 4-mis or vehicle. n = 5; **P < 0.01; NS, not signiﬁcant
(P > 0.05).
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(Fig. 5). The inhibition by antisense oligonucleotide was res-
cued by the addition of a stable analogue of TXA2 (Fig. 4C).
These results suggest that upregulation of TXS in colorectal
cancer cells results in increased production of TXA2 and the
released TXA2 induces proliferation of the cancer cells.
Recently, signiﬁcant roles of TXS in human cancer cells have
been reported in prostate [28] and bladder [29]. In human
prostate cancer cell lines, TXS inhibitors reduced the cell
migration, and overexpression of TXS accompanied an in-
crease in cell motility [28]. In human bladder cancer cell lines,
TXS inhibitors reduced the growth, migration and invasion
[29].
The occurrence of upregulation of TXS in the colorectal car-
cinoma is consistently very high among the samples from dif-
ferent patients (Fig. 1). The upregulation of TXS was not
parallel to that of COX-2 in the carcinoma (Figs. 1A and
S1A). It is noted that mRNA of nuclear factor E2 (NF-E2),
which binds to the NF-E2/AP1 site of the promoter region
of TXS [30], was overexpressed in the colorectal cancer tissue,
and that this overexpression of NF-E2 was positively and sig-
niﬁcantly correlated with that of TXS (r = 0.647, P < 0.05)
(Supplementary material, Fig. S3A). No signiﬁcant correlation
was observed between the expression levels of NF-E2 and
COX-2 (r = 0.350, P > 0.05) (Supplementary material,Fig. S3B). Therefore, the regulatory mechanism of expression
of TXS and COX-2 may be independent. In a future study, it is
necessary to clarify the mechanism of upregulation of NF-E2
in the colorectal cancer.
Inducible microsomal prostaglandin E synthase (mPGES),
which converts PGH2 to PGE2, was overexpressed in 83%
of human colorectal cancers [31]. An aberrant expression of
mPGES-1 in combination with COX-2 can contribute to
tumorigenesis [32]. PGE2 has been suggested to be associated
with colorectal carcinoma via two diﬀerent EP receptors: it
stimulates cell proliferation, invasion and migration via the
EP4 receptor [33] and angiogenesis via the EP2 receptor
[34]. Therefore, both the mPGES-PGE2 pathway and the
present TXS-TXA2 pathway are involved in colorectal carci-
noma. At present, the functional relationship between these
two pathways in the colorectal carcinoma is unknown and
it would be an interesting subject to be clariﬁed in a future
study.
In conclusion, we have found that TXS is overexpressed in
human colorectal carcinoma and TXA2 is involved in the colo-
nic cancer cell proliferation. As a novel function of TXA2 in
the colorectal carcinomas, we suggest that TXA2 stimulates
the cancer cell proliferation. For treatment of colorectal can-
cer, TXS inhibitors which block the production of TXA2
may be clinically eﬀective.
Fig. 5. Eﬀects of a TP antagonist, KW-3635, on the cell proliferation of a human colonic cancer cell line. (A) Concentration-dependent eﬀects of
KW-3635 on the STA2-induced proliferation of KM12-L4 cells are shown. STA2 (0.1 lM) and KW-3635 were added just after seeding of the KM12-
L4 cells. n = 5; *P < 0.05; **P < 0.01. (B) Eﬀects of KW-3635 and STA2 on the proliferation of KM12-L4 cells. STA2 (0.1 lM) or/and KW-3635
(20 lM) were added just after seeding of the cells. n = 5; **P < 0.01; NS, not signiﬁcant (P > 0.05). (C) Eﬀects of KW-3635 and STA2 on the
proliferation of the TXS-depleted KM12-L4 cells. STA2 (0.1 lM) or/and KW-3635 (20 lM) were added just after treating the cells with TXS-AS.
n = 5; NS, not signiﬁcant (P > 0.05). (D) Eﬀects of KW-3635 and STA2 on the proliferation of the 4-mis-treated KM12-L4 cells. STA2 (0.1 lM) or/
and KW-3635 (20 lM) were added just after treating the cells with 4-mis. n = 5; NS, not signiﬁcant (P > 0.05).
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Appendix A. Supplementary data
Supplementary data associated with this article can be
found, in the online version, at doi:10.1016/j.febslet.2006.
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